Quantifi: Jon Gregory on Challenges in xVA Pricing and Valuation

Jon speaks about regulation, quantification and usage & overlaps. Pricing, Valuation and Risk Management of OTC derivatives has been a large field and cover many different products. xVA has changed a lot of things people thought they knew about, simple things like the Black and Scholes formula. Fundamental things like this have been challenged within the derivatives world.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a RiskTech Forum account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: